Recent in vivo studies show that preserving DNA sequences while altering methylation patterns can be safe and efficacious, encouraging clinical aspirations.
Epicrispr has been named to Fierce Biotech’s 2023 “Fierce 15” list, designating it as one of the most outstanding early-stage biotechnology companies in the industry.
Epicrispr is championing the development of epigenetic therapies to modify gene expression, targeting a range of diseases not currently addressable with existing genetic medicines.
Focused in the field of epigenetics, U.S.-based Epicrispr was spun out of Stanford University in 2018. The startup has built the Gene Expression Modulation System (GEMS), its platform technology, to treat a number of diseases.
The biotechnology company Epicrispr presented preclinical data supporting the potential clinical progress of EPI-321 in treating facioscapulohumeral muscular dystrophy (FSHD).
The San Francisco-based company has taken a step forward with proof of concept for its ‘switch on or switch off’ approach to gene regulation via non-cutting CRISPR molecules.
To overcome the obstacles for CRISPR-Cas9 gene editing, the startup Epicrispr was launched in July 2022 with an impressive Series A round worth $55 million.
Epicrispr, founded by Stanford bioengineer Stanley Qi, builds pipeline with tiniest Cas protein, epigenetic modulators, a platform that combines them, and proceeds from $55M Series A.
Epicrispr is funded by Horizons Ventures and led by Amber Salzman, who has headed multiple genetic medicine companies, most recently Adverum Biotechnologies.
Controlling the epigenetics of a patient, figuring out what genes are expressed and understanding their level of expression, is at the center of a new company founded by Stanley Qi.
Epicrispr is controlling target gene expression using single vectors that combine its highly compact Cas protein with guide RNAs and epigenetic modulators.
A former doctoral candidate in CRISPR pioneer Jennifer Doudna’s lab founded a new biotech seeking to wade into “epigenetics-level gene editing,” and has now secured enough capital to do just that.
